Pharmaceutical company Sarepta Therapeutics announced Monday evening that it will temporarily halt all shipments of its Duchenne muscular dystrophy gene therapy Elevidys across the United States, following reports of three patient deaths linked to the treatment.
The company’s decision came shortly after Children’s Hospital Los Angeles suspended its use of the therapy. According to Sarepta, this temporary pause will provide time to address information requests and complete a safety labeling supplement process with the FDA.
Doug Ingram, CEO of Sarepta, acknowledged the difficulty of the decision, noting that patients with Duchenne muscular dystrophy face ongoing muscle deterioration and require disease-modifying treatments. Ingram emphasized the importance of maintaining a constructive relationship with the FDA, stating that the suspension was necessary to address regulatory concerns and complete the labeling process.
The announcement has significantly impacted Sarepta’s stock
performance, with shares declining an additional 4% in pre-market trading, following Monday’s 5.36% decrease. The company’s stock has experienced a dramatic 89% decline year-to-date, reaching levels not seen since 2015.
In a notable market reaction, HC Wainwright & Co. analyst Mitchell S. Kapoor downgraded Sarepta’s price target from $10 to zero while maintaining a sell rating. Current Bloomberg data shows mixed analyst sentiment, with three sell ratings, seventeen holds, and six buy recommendations. The average Wall Street price target stands at $28.32.
Barclays analyst Gena Wang cited ongoing regulatory uncertainties in her decision to take a neutral stance, particularly noting the “numerous twists and turns” in communications between the FDA and Sarepta following the third patient death. Wang established an $18 price target, suggesting a potential 35% upside from the previous closing price.
The events leading to the suspension began Friday when the FDA requested Sarepta to stop Elevidys shipments after reports emerged of a third patient death in clinical trials. Initially, Sarepta refused this request, triggering criticism from various stakeholders.
The company’s eventual decision to suspend shipments represents a significant shift in its approach to addressing safety concerns surrounding Elevidys. Sarepta emphasized its commitment to a “collaborative, science-driven review process” with the FDA, highlighting the importance of addressing any regulatory questions that may arise during this period.
This development marks a critical moment for both Sarepta and the broader gene therapy sector, as stakeholders closely monitor the implications of these safety concerns for future treatment
developments. The company’s willingness to cooperate with regulatory authorities, despite initial resistance, demonstrates the complex balance between providing innovative treatments and ensuring patient safety in the pharmaceutical industry.
The impact of this decision extends beyond Sarepta’s immediate business operations, affecting patients who rely on Elevidys as a treatment option for Duchenne muscular dystrophy. The temporary suspension highlights the ongoing challenges in developing and maintaining safe and effective gene therapies, while also underscoring the importance of regulatory oversight in protecting patient welfare.
As the situation continues to develop, the focus remains on the completion of the safety labeling supplement process and the restoration of confidence in Elevidys’ safety profile. The outcome of this regulatory review period could have lasting implications for both Sarepta’s future and the broader landscape of gene therapy treatments.